GlassScriptPhysician profile
Quy Pham
NPI 1487000154
$14,085.94
in general payments reported to CMS, 2019-2025
36 companies · $2,539 in 2025
The $2,539 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $224 · 2021: $2,040 · 2022: $2,827 · 2023: $3,094 · 2024: $3,362 · 2025: $2,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,443 · Education: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,443.18 |
| Education | $551.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,824.61 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $1,439.92 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $1,093.18 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $1,089.16 | 2020-2025 | Dupixent |
| Amgen INC. | $787.55 | 2020-2025 | Otezla, Otezla |
| Genzyme Corporation | $762.69 | 2021-2025 | |
| Janssen Biotech, INC. | $752.15 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $748.80 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $626.80 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $603.86 | 2021-2025 | Adbry |
| Ucb, INC. | $577.50 | 2020-2025 | Bimzelx |
| Dermavant Sciences, INC. | $576.96 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $397.78 | 2023-2025 | Zoryve |
| Hill Dermaceuticals, INC. | $369.40 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $349.02 | 2022-2025 | Sotyktu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $344.46 | 2021-2025 | |
| Revance Therapeutics, INC. | $340.37 | 2024-2025 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $265.41 | 2021-2025 | Cabtreo, Jublia, Arazlo |
| Galderma Laboratories, L.P. | $259.65 | 2020-2025 | Nemluvio, Aklief, Twyneo |
| Almirall LLC | $180.77 | 2021-2024 | Klisyri |
| Mayne Pharma Commercial LLC | $124.21 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $115.55 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $86.58 | 2020-2021 | |
| Botanix Sb INC | $68.16 | 2025 | Sofdra |
| Organon LLC | $62.58 | 2025 | Vtama |
| Organogenesis INC. | $38.08 | 2025 | Nushield |
| Blueprint Medicines Corporation | $31.44 | 2023 | |
| Kyowa Kirin, INC. | $24.85 | 2021 | |
| Epi Health, LLC | $24.19 | 2021 | |
| Biocon Biologics INC | $23.21 | 2025 | Hulio |
| Biofrontera INC. | $21.11 | 2021 | |
| Sanofi US Services INC. | $17.57 | 2024 | |
| Sebela Pharmaceuticals INC. | $16.46 | 2021 | |
| Strata Skin Sciences, INC. | $15.69 | 2023 | Xtrac |
| Journey Medical Corporation | $13.44 | 2023 | |
| Krystal Biotech INC | $12.78 | 2023 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quy Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.